Description
PRI-724 is an inhibitor of beta-catenin/CBP signaling and a potent antifibrotic agent.
PRI-724
Product ID P691320
Cas No. 1422253-38-0
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 1422253-38-0 |
|---|---|
| Purity | ≥98% |
| Formula | C33H35N6O7P |
| Formula Wt. | 658.65 |
| IUPAC Name | [4-[[(6S,9S,9aS)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-ylmethyl)-3,6,9,9a-tetrahydropyrazino[2,1-c][1,2,4]triazin-6-yl]methyl]phenyl] dihydrogen phosphate |
| Synonym | PRI724, Foscenvivint |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| Info Sheet |
|---|
References
Schmidtova S, Kalavska K, Liskova V, et al. Targeting of deregulated Wnt/beta-catenin signaling by PRI-724 and LGK974 inhibitors in germ cell tumor cell lines. Int J Mol Sci. 2021 Apr 20;22(8):4263. PMID: 33923996
Gabata R, Harada K, Mizutani Y, et al. Anti-tumor activity of the small molecule inhibitor PRI-724 against beta-catenin-activated hepatocellular carcinoma. Anticancer Res. 2020 Sep;40(9):5211-5219. PMID: 32878809
Okazaki H, Sato S, Koyama K, et al. The novel inhibitor PRI-724 for Wnt/beta-catenin/CBP signaling ameliorates bleomycin-induced pulmonary fibrosis in mice. Exp Lung Res. 2019 Sep;45(7):188-199. PMID: 31298961